Sugi Predict

Sugi Predict / Targets / ESR2

ESR2

Estrogen receptor beta · Q92731 · ESR2 on Sugi Atlas →

409,852 patent compounds predicted against ESR2, 208,590 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Raloxifene Raloxifene (SCHEMBL6144) 1.00 19/20
Raloxifene Raloxifene (SCHEMBL19077) 1.00 19/20
Raloxifene Raloxifene (SCHEMBL19078) 0.96 19/20
SCHEMBL27499 SCHEMBL27499 1.00 15/20
SCHEMBL45831 SCHEMBL45831 0.53 13/20
SCHEMBL45825 SCHEMBL45825 0.64 12/20
SCHEMBL49704 SCHEMBL49704 0.62 12/20
SCHEMBL26168 SCHEMBL26168 0.58 12/20
SCHEMBL50089 SCHEMBL50089 0.46 12/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9223) 1.00 11/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9224) 1.00 11/20
SCHEMBL21027 SCHEMBL21027 1.00 11/20
SCHEMBL35973 SCHEMBL35973 0.84 11/20
SCHEMBL18750 SCHEMBL18750 0.80 11/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9372) 0.78 11/20
SCHEMBL25881 SCHEMBL25881 0.58 11/20
SCHEMBL26947 SCHEMBL26947 0.58 11/20
SCHEMBL18139 SCHEMBL18139 0.43 11/20
Bisphenol A Bisphenol A (SCHEMBL15062) 1.00 10/20
SCHEMBL27277 SCHEMBL27277 1.00 10/20

Clinical trials — most relevant to ESR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? PHASE4COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women PHASE3COMPLETED
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation PHASE3UNKNOWN
Maintenance Hormonal Therapy and DLBCL PHASE2/PHASE3NOT_YET_RECRUITING
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC PHASE3RECRUITING
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Phase II Study of Single Agent Lenvatinib PHASE2UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor PHASE2RECRUITING
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites PHASE2COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer PHASE2UNKNOWN
Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women PHASE1COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Sexual Hormones and Haemostasis: Observations for Women Health nanUNKNOWN
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen nanUNKNOWN
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer nanUNKNOWN
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? nanUNKNOWN
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer nanCOMPLETED
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus nanCOMPLETED
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer nanCOMPLETED
Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. nanCOMPLETED
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ESR2 binder may also engage these)

ProteinNameSimilarity
Q9XSW2 — 1.000 Q9XSW2 →
Q9TU15 — 1.000 Q9TU15 →
Q9XSB5 — 1.000 Q9XSB5 →
O08537 — 1.000 O08537 →
Q62986 — 1.000 Q62986 →
Q9PVE2 — 1.000 Q9PVE2 →
Q95171 — 1.000 Q95171 →
P50241 — 1.000 P50241 →
Q9W6M2 — 1.000 Q9W6M2 →
P19785 — 1.000 P19785 →
P06212 — 1.000 P06212 →
Q9PTU5 — 1.000 Q9PTU5 →
Q9TV98 — 0.999 Q9TV98 →
P06211 — 0.999 P06211 →
P57717 — 0.998 P57717 →
Q9YH32 — 0.998 Q9YH32 →
Q91250 — 0.998 Q91250 →
P57782 — 0.997 P57782 →
Q53AD2 — 0.997 Q53AD2 →
P51448 — 0.997 P51448 →
Q29040 — 0.997 Q29040 →
P50242 — 0.997 P50242 →
P49884 — 0.997 P49884 →
A0JNE3 — 0.997 A0JNE3 →
P57753 — 0.996 P57753 →
O93511 — 0.996 O93511 →
ESR1 Estrogen receptor 0.996 landscape →
F1QLY4 — 0.996 F1QLY4 →
O42132 — 0.995 O42132 →
Q9YGL3 — 0.995 Q9YGL3 →